Datroway Extends Survival in Metastatic Triple-Negative Breast Cancer
TL;DR
Datroway demonstrated a significant improvement in overall survival and progression-free survival in a Phase III trial for patients with metastatic triple-negative breast cancer who cannot receive immunotherapy, marking a potential breakthrough in treatment options for this high-risk group.
Topics:businesshealthcare#breast-cancer#datroway#healthcare#metastatic-tnbc#overall-survival#tropion-breast02
- Datroway demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option in TROPION-Breast02 AstraZeneca
- Astra, Daiichi Say Drug Extends Lives of Breast Cancer Patients Bloomberg.com
- AstraZeneca and Daiichi's Datroway boosts overall survival in breast cancer trial Yahoo
- AstraZeneca’s DATROWAY shows survival benefit in metastatic TNBC Investing.com
- AstraZeneca Partner Daiichi Sankyo Says Breast Cancer Drug Demonstrates Improvements in Primary Endpoints in Phase 3 Trial MarketScreener
Want the full story? Read the original reporting
Read on AstraZeneca